Previous 10 | Next 10 |
Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...
GuardantINFORM ™ platform offers real-world evidence to identify unmet need for patients with advanced breast cancer sGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present new data demonstrating the benefits of u...
Corporate insiders rang the bell on the market almost three weeks ago with elevated levels of insider selling. A third insider of a trillion-dollar market cap company joined the selling spree last week with Microsoft CEO Satya Nadella selling almost exactly half of his shares over. ...
Goldman Sachs identifies changes in popularity for stocks among hedge funds for indications of potential outperformance and underperformance. "During the last 19 years, stocks with the largest increase in the number of hedge fund investors ('Rising Stars') have typically gone on to outperform...
Guardant Health (GH +12.8%) co-CEO, AmirAli Talasaz bought 104,500 shares, bringing total share count to ~1.85M. Co-CEO, Helmy Eltoukhy bought 104,500 shares, bringing total share count to ~1.96M. News from last month, 'Guardant Health rebounds after deciding against buying NeoGenomics' For...
The study, published in Nature Medicine , demonstrates that the Guardant360 ® test helps identify patients who may benefit from treatment and can identify alterations that predict resistance Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology co...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – November 11, 2021 – New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force (USPSTF) and from the US Food and Drug Administration ar...
Image source: The Motley Fool. Guardant Health Inc (NASDAQ: GH) Q3 2021 Earnings Call Nov 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Guardant Health Inc (GH) Q3 2021 Earnings Call Transcript
Guardant Health, Inc. (GH) Q3 2021 Earnings Conference Call November 04, 2021 04:30 PM ET Company Participants Carrie Mendivil - Investor Relations Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Conference Call Part...
Guardant Health (NASDAQ:GH): Q3 GAAP EPS of -$1.06 misses by $0.12. Revenue of $94.78M (+27.1% Y/Y) beats by $2.19M. Press Release Reported 22,806 tests to clinical customers and 4,839 tests to biopharmaceutical customers in the third quarter of 2021, representing an increase of 35% and 58%, ...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company’s ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / ...
New research demonstrates value of epigenomic analysis and methylation sequencing with Guardant liquid biopsy portfolio across continuum of cancer care New data show strong performance of Guardant Reveal™ in detection and quantification of residual disease in early-stage breast can...